Advertisement
Data on PBI-1737, PBI-0110 and PBI-1308 were presented in poster sessionsas follows:
Dr. Mouna Lagroui, ProMetic's Research Scientist, presented data onPBI-1737 in prostate cancer. Results demonstrated that PBI-1737 displayedsignificant antitumor activity in human prostate cancer both in vitro and invivo. The in vivo study demonstrated a significant reduction in tumor volumeboth alone (p < 0.05) and in combination with cyclophosphamide (p < 0.01).
Advertisement
Dr. Lyne Gagnon, ProMetic's Director of Research and Development, Biology,presented preclinical data on the PBI-0110 alone and in combination withgemcitabine in intradermal and orthotopic pancreatic cancer. The study showedthat PBI-0110 alone significantly inhibited pancreatic tumor growth in mousemodels by as much as 58 percent (p < 0.05) after 44 days. The study alsodemonstrated a dose dependent inhibition of tumor growth, with the 400mg/kgdose being the most effective, inhibiting growth by nearly 40 percent after 25days (p < 0.05). Combination therapy of 100mg/kg PBI-0110 and gemcitabinedemonstrated similar efficacy. Finally, the study demonstrated increasedsurvival in mice that received the combination therapy of PBI-0110 200mg/kgand gemcitabine.
Finally, Dr. Brigitte Grouix, ProMetic research scientist, presented dataon PBI-1308, which demonstrated a reduction of inflammation and cancer cellproliferation through inhibition of NF-kappaB in prostate cancer andinhibition of TNF-alpha, and inflammatory cytokine.
"We continue to be very proud of the progress our compounds are making inearly-stage cancer research," said Pierre Laurin, president and CEO ofProMetic Life Sciences, Inc. "We are assembling a broad pipeline of promisingcandidates for various cancers, which augments PBI-1402, our lead compoundwhich has shown compelling human data for the treatment ofchemotherapy-induced anemia."
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceuticalcompany specialized in the research, development, manufacture and marketing ofa variety of commercial applications derived from its proprietary MimeticLigand(TM) technology. This technology is used in large-scale purification ofbiologics and the elimination of pathogens. ProMetic is also active intherapeutic drug development with the mission to bring to market effective,innovative, lower cost, less toxic products for the treatment of hematologyand cancer. Its drug discovery platform is focused on replacing complex,expensive proteins with synthetic "drug-like" protein mimetics. Headquarteredin Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. andCanada, manufacturing facilities in the U.K. and business developmentactivities in the U.S., Europe, Asia and in the Middle-East.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic'sobjectives, strategies and businesses that involve risks and uncertainties.These statements are "forward-looking" because they are based on our currentexpectations about the markets we operate in and on various estimates andassumptions. Actual events or results may differ materially from thoseanticipated in these forward-looking statements if known or unknown risksaffect our business, or if our estimates or assumptions turn out to beinaccurate. Such risks and assumptions include, but are not limited to,ProMetic's ability to develop, manufacture, and successfully commercializevalue-added pharmaceutical products, the availability of funds and resourcesto pursue R&D projects, the successful a
